Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
ELRiSE MDS trial: what clinicians have said so far
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
- NCT07422480 ↗
- Recruiting
- Takeda
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on ELRiSE MDS (elritercept) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ELRiSE MDS so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Myelodysplastic Syndrome; Anemia
- Interventions
- Elritercept; Epoetin Alfa
- Arms
- Elritercept · Experimental
- Epoetin Alfa · Active comparator
- Enrollment
- 300 (estimated)
- Primary outcomes
- Proportion of Participants who are RBC Transfusion Independent (RBC-TI) for any Consecutive Greater Than Equal to (≥) 12-Week Period From Day 1 Through 24 Weeks With Concurrent Mean Hemoglobin (Hgb) Increase ≥ 1.5 Grams per Deciliter (g/dL) From Baseline
- Sponsor
- Takeda
- Start
- May 21, 2026
- Primary completion
- Apr 30, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07422480 · updated Nov 6, 2026